Antisense Therapeutics Limited (ANP) - Research

$0.047 0.003 (6%)

ANP General Information +

ASX Code ANP
Website http://www.antisense.com.au
GICS Sub-Industry Pharmaceuticals
Market Cap ($M) 19
Current Price $0.047
Day High $0.048
Day Low $0.047
Last Close $0.050
Price Movement $0.00 ( 6% )
Prices as at 16:40, 24 Jun 2019
+Security prices are delayed by at least 20 minutes and are indicative only.

ANP Company Overview

Business Description

Antisense Therapeutics Limited (ANP) is an Australian publicly traded biopharmaceutical drug discovery and development company whose mission is to create, develop and commercialize novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy (DMD), Multiple Sclerosis (MS), and Acromegaly. ANP has three products including ATL1102 injection for Multiple Sclerosis, ATL1103 injection for growth & sight disorders, and ATL1102 inhaled for asthma.

ANP Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2018 A -2.33 -1.20 0.00% 0.00 0.00 0.00% 0.0%
2017 A -2.75 -1.50 0.00% 0.00 0.00 0.00% 0.0%
2016 A -2.51 -1.30 0.00% 0.00 0.00 0.00% 0.0%

ANP Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2016 A 2017 A 2018 A 2016 A 2017 A 2018 A 2016 A 2017 A 2018 A
Antisense Therapeutics (ANP) $21M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mayne Pharma Group (MYX) $807M -0.5645 -0.2404 0.7615 17.7700 23.3945 13.2813 0.00% 0.00% 0.00%
Starpharma (SPL) $498M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

ANP Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 4.12 0.00
Market 0.61 15.00 1.17 0.97
Sector 0.96 29.20 3.16 2.11

ANP Directors

Name Position Start Date
Mr Mark P Diamond Chief Executive Officer, Managing Director 31 Oct 2001
Mr Robert William Moses Non-Executive Chairman, Non-Executive Director 23 Oct 2001
Professor Graham Mitchell Non-Executive Director 24 Oct 2001
Dr Gary W Pace Non-Executive Director 9 Nov 2015
Mr William Goolsbee Non-Executive Director 15 Oct 2015

ANP Management

Name Position
Phillip Hains Chief Financial Officer,Company Secretary
George Tachas Director, Drug Discovery & Patents

ANP Substantial Shareholders

Holding Name
70,833,333 (19.06%) National Nominees Limited
21,906,913 (5.89%) HSBC Custody Nominees (Australia) Limited

ANP Calendar of Events

Date Event
26 February 2020 Report (Interim)
28 October 2019 Report (Annual)
28 August 2019 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.